Key Highlights

  • Teva held its first-ever R&D Day, setting a target of $6 billion to $7 billion in innovative medicines Revenue by 2030.
  • Innovative medicines revenue has more than doubled since the company launched its Pivot to Growth strategy in 2023.
  • The pipeline has more than $10 billion in peak sales potential, according to the company.
  • Teva says it has returned to Investment grade and generated more than $6 billion in free Cash Flow from 2023 to 2025.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) hosted its first-ever R&D Day on November 11, 2026, laying out a plan to generate $6 billion to $7 billion in innovative medicines revenue by 2030. Teva is listed on the New York Stock Exchange and the Tel Aviv Stock Exchange. Chief Executive Richard Francis presented the company’s growth path alongside members of its executive and R&D teams, with a focus on its advancing pipeline and its approach to research.

The event centered on the next phase of Teva’s strategy after the Pivot to Growth program that began in 2023. The company used the event to outline the potential of its pipeline and the commercial capacity it expects to bring to new launches.

Progress Since the Pivot to Growth Strategy

Teva said it has more than doubled revenue from innovative medicines since 2023, a segment it now says makes up more than 20 percent of total revenue. Its gross Margin has improved to approximately 55 percent, and the company said it has seven late-stage pipeline Assets with high-value potential. Three key innovative products are cited as central to that growth.

The company also highlighted progress in its generics and Biosimilars businesses. It said the generics Business has been stabilized in recent years, and that biosimilar revenue is expected to double from 2024 to 2026. Those trends help explain how Teva has reshaped its mix toward branded products while keeping a large generics base.

Pipeline, R&D Model and Launch Ambitions

Richard Francis said the company’s R&D engine is designed to turn proven science into new medicines, with the potential for one new launch annually through 2030. The pipeline is said to carry more than $10 billion in peak sales potential, a figure that reflects the expected value of products if they reach their full market potential.

Teva also said it will present updates on its late-stage growth drivers, early-stage assets, in-house antibody discovery capabilities and commercial and financial strengths during the event. Those updates are meant to show how the company plans to support its future innovation wave, though the path from clinical development to revenue carries well-known risks.

Financial Commitments and the Road to 2030

Teva said it has returned to investment grade and has generated more than $6 billion in free cash flow over the period from 2023 to 2025. That cash flow gives the company a basis for funding research and launches, though the 2030 target still depends on approvals, competition and pricing.

Reaching the $6 billion to $7 billion goal will require sustained execution across launches and commercial operations. Drug Development is lengthy and uncertain, and pricing pressure in key markets can reduce returns even when products are approved, so investors will judge progress against milestones and quarterly revenue trends.

Final Word

Teva has set a 2030 target of $6 billion to $7 billion in innovative medicines revenue and used its first R&D Day to outline how its pipeline and commercial capabilities will support that goal. Growth so far has come from its branded products, while the generics business has been stabilized. The company’s progress will be measured through launches, pipeline readouts and quarterly revenue from its innovative medicines.